Search

Displaying results 4121 - 4130 of 7604 in total
  1. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor and its psychopharmacological profile differs from such … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.

  2. Drug

    Ponazuril

    go.drugbank.com/drugs/DB11452
    ExperimentalVet approved

    Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.

  3. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]

  4. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).

  5. Drug

    AAV-AIPL

    go.drugbank.com/drugs/DB17857
    Experimental

    Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.

  6. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. … It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  7. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  8. Drug

    Becotatug

    go.drugbank.com/drugs/DB19069
    Investigational

    Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations). … Becotatug is under investigation in clinical trial NCT06380348 (JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung

  9. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.

  10. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.